Psilocybin vs LSD: The Neuroscience

Ask a room of people how LSD and psilocybin differ and you will get confident answers: LSD is longer, sharper, more visual and cerebral; mushrooms are warmer, more emotional, more “of the earth.” Some of that folklore holds up. Most of it dissolves the moment you put the two molecules under controlled conditions. Beneath the surface, psilocybin and LSD are the two archetypal classic psychedelics, and they share the same core mechanism — agonism at the serotonin 5-HT2A receptor. The best head-to-head study we have found that once you match them for dose and duration, the quality of the experience is remarkably alike. This is a comparison of two drugs that are far more similar than the culture around them believes — and where the real differences actually lie. This article is education, not medical advice.

OOTW has covered each on its own — Your Brain on Psilocybin and LSD: The Neuroscience. This piece sets them side by side, both to make the contrast legible and to separate what the rigorous data actually show from the folklore that surrounds them. (Educational overview only — not medical or use advice.)

The shared engine: one receptor, two molecules

Start with what unites them, because it is bigger than what divides them. Both psilocybin and LSD are serotonergic 5-HT2A receptor agonists, and this is not a minor detail: blocking 5-HT2A abolishes the subjective psychedelic effects of both, which is why the receptor is the accepted primary driver of the classic-psychedelic state (Sharp et al., Br. J. Pharmacol. 2025). Psilocybin itself is a prodrug: the body rapidly dephosphorylates it to psilocin, the molecule that actually does the work. LSD needs no such conversion. But both arrive, ultimately, at the same cortical door — the 5-HT2A receptor densely expressed on layer-5 pyramidal neurons that we unpack in The 5-HT2A Receptor. Everything else in this comparison is a variation on that shared theme.

The comparison at a glance

Where they diverge: promiscuity, potency, and a receptor “lid”

The pharmacological differences are real but secondary. LSD is promiscuous. Beyond 5-HT2A it activates 5-HT1A/1B/2C/5/6/7, dopamine D1–D3, and adrenergic receptors; those extra targets — especially D2-mediated effects — are thought to color LSD’s later-phase, more energetic and stimulant-like character, even though 5-HT2A remains primary for the trip itself (Wacker et al., Cell 2017; Marona-Lewicka et al., 2005). Psilocin is comparatively more 5-HT2-selective, binding 5-HT2A (Ki ≈ 120–173 nM), 5-HT2C, and 5-HT1A with broadly comparable affinities but with weaker, less consistent dopaminergic/adrenergic activity — a more serotonin-centric profile.

Then there is the elegant piece of structural biology that explains LSD’s legendary potency. LSD dissociates from the 5-HT2A receptor extraordinarily slowly, because a part of the receptor (extracellular loop 2) folds a “lid” over the bound molecule and traps it — a residence time of ~221 minutes for the wild-type receptor, dropping to ~50 minutes when the lid residue is mutated (Wacker et al., 2017). This kinetic trapping helps explain how tiny microgram doses of LSD produce effects lasting many hours, while psilocin binds with lower affinity, clears faster, and therefore needs milligram doses and delivers a shorter experience — LSD is roughly ~100× more potent by mass.

Duration: the one difference that is actually robust

The definitive comparison is the Holze/Liechti double-blind, placebo-controlled crossover in Basel: 28 healthy adults, five 25-hour sessions each (placebo, LSD 100 & 200 µg, psilocybin 15 & 30 mg). Its headline finding is disarmingly simple. At matched intensity, the quality of the altered state is remarkably similar — the main difference is that LSD simply lasts longer: about 9.3 hours for LSD versus 5.6–6.5 hours for psilocybin (Holze et al., Neuropsychopharmacology 2022). The study also calibrated equivalence: 100 and 200 µg of LSD produced overall subjective intensity comparable to 30 mg psilocybin, while 15 mg psilocybin was clearly weaker. In other words, the folk intuition that these are fundamentally different kinds of experience is mostly wrong; the durable, measurable difference is the length of the day they ask of you.

Phenomenology: folklore versus the controlled data

That said, softer contrasts are consistently reported, and it is worth being precise about their evidentiary weight. The cardiovascular signature genuinely differs: psilocybin raised blood pressure more, while LSD raised heart rate more, though overall cardiostimulation was comparable (Holze et al., 2022). Beyond that, LSD is often described as more energetic, stimulating, and “electric,” with a longer, more cognitively activated arc (consistent with its dopaminergic/adrenergic breadth), and psilocybin as more emotional, introspective, embodied, and “earthy,” with a gentler taper. But these are widely reported tendencies, not robustly quantified differences — and the controlled data emphasize similarity once duration is accounted for (Psychiatric Times summary). The honest framing: trust the duration difference; hold the “vibe” differences loosely.

The brain on both: nearly the same scan

Neuroimaging reinforces the theme of similarity. Both drugs produce the common signature behind the entropic brain model. Both acutely reduce the integrity and within-network connectivity of the default mode network — the self-referential system whose breakdown is the leading neural correlate of ego dissolution — while increasing neural entropy and cross-network connectivity, flattening the brain’s usual hierarchical control (Carhart-Harris et al., 2014; DMN systematic review, 2022). LSD-specific multimodal imaging adds increased visual-cortex connectivity and whole-brain integration that correlate with ego-dissolution and visual imagery (Carhart-Harris et al., PNAS 2016), while for psilocybin the degree of network disintegration tracks with plasma psilocin level and the intensity of the subjective experience. The two imaging signatures are, again, more alike than different — exactly what the shared 5-HT2A mechanism predicts.

Neuroplasticity: the same molecular route

Both drive rapid structural neuroplasticity through a shared pathway. A single dose of psilocybin produced roughly 10% increases in dendritic-spine size and density in mouse frontal cortex within 24 hours, persisting about a month (two-photon imaging) (Shao et al., Neuron 2021). The classic psychedelics — LSD, psilocybin, and DMT alike — promote neuritogenesis, spinogenesis, and synaptogenesis via 5-HT2A, TrkB, and mTOR signaling, and may even bind the BDNF receptor TrkB directly (Vargas/Olson et al., Science 2023; Moliner et al., 2023). In humans, even low-dose LSD acutely raised blood BDNF (Hutten et al., 2021). This plasticity is a leading candidate mechanism for both drugs’ durable therapeutic effects — though the causal chain from spine growth to clinical benefit in humans remains an inference, not a proven fact. We go deeper in BDNF and Neuroplasticity.

The clinic in 2026: psilocybin is further along

Here the two diverge on timeline, not mechanism. Psilocybin has the larger, later-stage depression base: COMPASS Pathways’ COMP360 hit its primary endpoint in two pivotal Phase 3 trials for treatment-resistant depression — COMP005 (a single 25 mg dose, June 2025) and COMP006 (~600 patients, two 25 mg doses beating a 1 mg control at week 6, with 26-week durability, February 2026) — with an NDA anticipated and FDA Breakthrough Therapy designation in hand (COMPASS, 2025; Psychiatric Times, 2026). LSD is moving fast but trails: MindMed’s MM120 (lysergide) earned FDA Breakthrough Therapy designation for generalized anxiety disorder after a Phase 2b showed a ~65% response and ~48% remission sustained to 12 weeks, and is now in Phase 3 — Voyage and Panorama in GAD, Emerge in MDD — with topline data reading out through 2026 (MindMed, 2025). Psilocybin’s shorter session (~half of LSD’s) is also a practical advantage for scaling supervised, in-clinic dosing. (Both programs are industry-sponsored, and psychedelic trials face well-documented functional-unblinding and expectancy issues that temper effect-size interpretation.)

Safety: two of the physically safest drugs known

On physiology, both are remarkably benign. Both classic psychedelics have very low physiological toxicity and a wide margin between active and dangerous doses, with no known lethal overdose from the drug’s direct pharmacology at typical doses — only modest, transient cardiovascular stimulation (Holze et al., 2022). Neither is physically addictive, and both show rapid tolerance. The dominant real-world risk for both is a challenging experience — acute anxiety, panic, or destabilization — strongly modulated by mindset, setting, screening, and support, with a personal or family history of psychosis a standard contraindication. HPPD (Hallucinogen Persisting Perception Disorder) is a recognized but rare outcome; the chronic form is estimated at roughly 1 in 50,000 users, and of people reporting long-term perceptual changes, somewhat more attributed them to LSD (~39%) than psilocybin (~11%) (Müller et al., 2022). The one clear relative difference: LSD’s much longer duration means a longer window for a difficult experience to unfold and a greater monitoring burden, while psilocybin’s shorter arc is generally easier to manage.

Legality in 2026

Federally, both psilocybin and LSD are Schedule I under the Controlled Substances Act. The state picture is where they part ways. Psilocybin has regulated adult access: Oregon (Measure 109) permits supervised use at licensed service centers, and Colorado (Proposition 122) decriminalized personal use and licenses “healing centers,” covering psilocybin, psilocin, DMT, ibogaine, and mescaline (mindmedicinelaw state guide, 2026). LSD is excluded from both frameworks and has no state-legal access anywhere in the US. An April 18, 2026 federal executive order directed FDA/DEA to accelerate psychedelic research (naming psilocybin, MDMA, ibogaine, and LSD) but did not legalize or reschedule anything. (Verify current law where you live; this is not legal advice.)

The honest bottom line

The most useful thing to hold onto is counterintuitive: psilocybin and LSD are far more alike than the culture around them suggests. Same primary receptor (5-HT2A), same DMN collapse and entropy surge, same plasticity pathway, similar phenomenology once you match the dose. The robust, reliable difference is duration — LSD asks for a ~9–12 hour day, psilocybin for ~4–6 hours — downstream of LSD’s ultra-long receptor residence time and broader (dopaminergic) pharmacology. In the clinic, psilocybin is currently the frontrunner, with two positive Phase 3 depression trials to LSD’s still-reading Phase 3 program, and its shorter session is a practical edge. If you take one thing from this comparison, take the reframing: the interesting question is not “which is stronger” but “how long do you want the door to stay open.”

OOTW Journal is educational and does not provide medical advice. Psilocybin and LSD are Schedule I substances in most of the US. Although both have high physiological safety margins, their psychological risks are real and depend heavily on set, setting, dose, and mental-health history — a personal or family history of psychosis is a standard contraindication, and challenging experiences can be destabilizing. This article is not a guide to using either substance. If you are in crisis, contact a local emergency line or the 988 Suicide and Crisis Lifeline (US). This article is education, not medical advice.